Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 -0.5%
EPS Growth %: -31.3%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: -31.3%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.75, $0.13 better than the analyst estimate of $0.62. Revenue for the quarter came in at $270.7 million versus the consensus estimate of $270.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Schneider National (SNDR) PT Raised to $34 at Stifel
- Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
